Ftse Mib
34.252,37
-0,36%
DAX
18.470,95
-0,69%
S&P 500
5.648,92
0,31%
NASDAQ
18.537,64
0,35%
Bitcoin
63.449,14
-2,16%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Sanofi (SAN) Sanofi (SAN) Notizie

SAN

Sanofi (SAN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:SAN
DataOraFonteTitoloSimboloCompagnia
28/07/202207:30GlobeNewswire Inc.Press Release: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare DiseaseEU:SANSanofi
28/07/202207:30GlobeNewswire Inc.Communiqué de presse : Forte performance au T2 : hausse des perspectives 2022 et nombreuses avancées R&D en immunologie et maladies raresEU:SANSanofi
20/07/202218:52GlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares – June 2022EU:SANSanofi
20/07/202218:52GlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions – JUIN 2022EU:SANSanofi
18/07/202212:32Dow Jones NewsBOURSE: GSK chute après la scission de Haleon qui fait ses premiers pas en BourseEU:SANSanofi
14/07/202207:48Dow Jones NewsSanofi: résultats positifs pour le Dupixent dans l'œsophagite à éosinophiles de l'enfantEU:SANSanofi
14/07/202207:00GlobeNewswire Inc.Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitisEU:SANSanofi
14/07/202207:00GlobeNewswire Inc.Communiqué de presse: Résultats positifs de phase III pour Dupixent® (dupilumab) dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 1 à 11 ansEU:SANSanofi
10/07/202215:45GlobeNewswire Inc.Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxisEU:SANSanofi
10/07/202215:45GlobeNewswire Inc.Une prophylaxie par fitusiran a réduit de 61% les saignements chez les personnes atteintes d’hémophilie A ou B, avec ou sans inhibiteurs, comparativement à une prophylaxie antérieure par facteur de remplacement ou par agent court-circuitantEU:SANSanofi
10/07/202215:45GlobeNewswire Inc.Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxisEU:SANSanofi
10/07/202215:45GlobeNewswire Inc.Des données pivots démontrent que l’efanesoctogog alpha une fois par semaine confère une protection supérieure contre les saignements, comparativement à une prophylaxie antérieure par facteur de remplacementEU:SANSanofi
04/07/202212:00GlobeNewswire Inc.Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countriesEU:SANSanofi
04/07/202212:00GlobeNewswire Inc.Sanofi Global Health lance la marque Impact® à but non lucratif pour 30 médicaments destinés aux pays à faible revenuEU:SANSanofi
30/06/202217:42Dow Jones NewsSanofi on Pace for Largest Percent Decrease Since April 2020 -- Data TalkEU:SANSanofi
30/06/202212:29Dow Jones NewsSanofi's Phase 3 Trials of Multiple Sclerosis Drug Partially Paused by FDAEU:SANSanofi
28/06/202208:17Dow Jones NewsSanofi: la Commission européenne approuve les traitements Nexviadyme et XenpozymeEU:SANSanofi
28/06/202207:30GlobeNewswire Inc.Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMDEU:SANSanofi
28/06/202207:30GlobeNewswire Inc.Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe DiseaseEU:SANSanofi
28/06/202207:30GlobeNewswire Inc.Communiqué de presse: Xenpozyme® (olipudase alpha) approuvé par la Commission européenne – premier et seul traitement du déficit en sphingomyélinase acideEU:SANSanofi
28/06/202207:30GlobeNewswire Inc.Communiqué de presse: Nexviadyme® (avalglucosidase alpha), nouveau traitement de référence potentiel de la maladie de Pompe, a été approuvé par la Commission européenneEU:SANSanofi
27/06/202222:57GlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares – May 2022EU:SANSanofi
27/06/202222:57GlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions – MAI 2022EU:SANSanofi
24/06/202220:05Dow Jones NewsSanofi On Pace for Largest Percent Increase Since November 2020 -- Data TalkEU:SANSanofi
24/06/202208:21Dow Jones NewsSanofi, GSK Report Successful Vaccine Study Against OmicronEU:SANSanofi
24/06/202208:15Dow Jones NewsLe vaccin de Sanofi et GSK avec l'antigène Bêta démontre son efficacité contre OmicronEU:SANSanofi
24/06/202207:32GlobeNewswire Inc.Availability of the Q2 2022 Memorandum for modelling purposesEU:SANSanofi
24/06/202207:32GlobeNewswire Inc.Mise en ligne du document «Q2 2022 Memorandum for modelling purposes»EU:SANSanofi
24/06/202207:28GlobeNewswire Inc.Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccineEU:SANSanofi
13/06/202208:43Dow Jones NewsSanofi-GSK Covid-19 Booster Showing Strong Immune Response, Sanofi SaysEU:SANSanofi
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:SAN

La tua Cronologia

TSXV
GBR
Great Bear Resources
LSE
ESO
Epe Special Opportunities
BOV
CSNA3
SID NACIONAL ON
LSE
HAN
Hansa Investment
AQSE
NANO.GB
Nanoco
LSE
JET2
Jet2
NASDAQ
CATY
Cathay General Bancorp
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network